Cologuard, made by Exact Sciences, sponsored a golf tournament this year. Photo: Darren Carroll/Getty Images

Exact Sciences, maker of the colon cancer test Cologuard, has signed a multimillion deal with drug giant Pfizer to increase and share in the costs of marketing the test — a move Wall Street cheered yesterday.

The bottom line: Physicians and other medical professionals should be ready for an onslaught of calls and face-to-face pitches from the companies' sales armies, even though there is evidence the costly Cologuard test can lead to false positives.

The big picture: This marketing blitz inevitably will push more people to get checked for colon cancer, which public health experts say is a good thing. Colon cancer is the second-leading cause of cancer death in the U.S.

But experts also say it will come at a steep price with potentially harmful and wasteful care.

  • A doctor must prescribe Cologuard, an FDA-approved home kit where people mail their stool to a lab for DNA testing.
  • Medicare pays $509 for Cologuard. Most other commercial health insurers cover it, and likely pay more than Medicare.
  • The U.S. Preventive Services Task Force says Cologuard is acceptable for colon cancer screening. But when compared with cheaper tests, Cologuard was tied to "more false-positive results, more diagnostic colonoscopies, and more associated adverse events per screening test," and it "may potentially lead to overly intensive surveillance," according to the USPSTF.
  • "Worried patients and/or providers may feel obligated to order additional tests — which could be imaging or invasive — to determine whether there could be a cancer elsewhere in the body, thus potentially adding to the costs and risks of Cologuard screening," Richard Hoffman, a professor of internal medicine and epidemiology at the University of Iowa, said in an email.
  • An Exact Sciences spokesperson referred to a company-funded study on why it believes Cologuard is better than other tests.

By the numbers: The financial terms of the agreement are lucrative for both sides.

  • Pfizer will spend nearly $70 million in Cologuard marketing and promotion from October through the end of 2021.
  • Exact Sciences will maintain its baseline marketing spend of at least $80 million per year and match Pfizer's additional spending.
  • Any profits that are earned over certain Cologuard revenue thresholds will be split 50-50, and Pfizer can get a royalty of up to 3% of Cologuard sales for three years after the deal ends in 2021.
  • A Pfizer executive told investors it made the deal because it had a sales team for Lyrica, a drug that is losing market exclusivity, that could shift to Cologuard instead.
  • Exact Sciences expects to bring in at least $1.2 billion in Cologuard revenue by 2021.
  • CEO Kevin Conroy made almost $50 million over the past three years, including $32.3 million in 2017.

Go deeper

Updated 3 mins ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Global: Total confirmed cases as of 3 p.m. ET: 11,143,945 — Total deaths: 527,681 — Total recoveries — 6,004,593Map.
  2. U.S.: Total confirmed cases as of 3 p.m. ET: 2,818,588 — Total deaths: 129,584 — Total recoveries: 883,561 — Total tested: 34,213,497Map.
  3. States: Photos of America's pandemic July 4 ICU beds in Arizona's hot spot reach near capacity.
  4. Public health: U.S. coronavirus infections hit record highs for 3 straight days.
  5. Politics: Trump extends PPP application deadlineKimberly Guilfoyle tests positive.
  6. World: Mexican leaders call for tighter border control as infections rise in U.S.
  7. Sports: 31 MLB players test positive as workouts resume.
  8. 1 📽 thing: Drive-in movie theaters are making a comeback.
28 mins ago - Health

In photos: America celebrates July 4 during global pandemic

Photo: Francine Orr/Los Angeles Times/Getty Images

The U.S. has already celebrated Easter, graduations and so much more during the coronavirus pandemic, and now it can add July 4 to the list.

The state of play: Axios' Stef Kight writes public parades and fireworks displays around much of the country are being canceled to prevent mass gatherings where the virus could spread. Hot-dog contests and concerts will play to empty stands and virtual audiences — all while American pride treads an all-time low.

3 hours ago - Health

U.S. coronavirus infections hit record highs for 3 straight days

Illustration: Aïda Amer/Axios

The U.S. has reached new highs in single-day coronavirus infections for three consecutive days this week, per data from Johns Hopkins and the COVID Tracking Project.

The big picture: The number of coronavirus cases increased in the vast majority of states over the last week, and decreased in only two states plus the District of Columbia, Axios' Andrew Witherspoon and Caitlin Owens report.